JAB-3312

· Allist Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for JAB-3312, covering 2025-04-04 to 2025-12-29. Get the full timeline:

Most recent: Clinical Trial Update: A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors [Phase 1]